Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462276 | 1.00 | BRAF (0.51) | BRAFFLT3HCKSRCMAPK12 | |
| SCHEMBL22919879 | 0.88 | BRAF (0.54) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL9909782 | 0.86 | BRAF (0.52) | BRAFFLT3 | |
| SCHEMBL29988147 | 0.86 | BRAF (0.52) | BRAFFLT3 | |
| SCHEMBL3757667 | 0.85 | BRAF (0.59) | BRAF | |
| SCHEMBL3052932 | 0.83 | BRAF (0.70) | BRAF | |
| SCHEMBL24802203 | 0.82 | BRAF (0.64) | BRAFMET | |
| SCHEMBL30814305 | 0.82 | BRAF (0.64) | BRAFMET | |
| SCHEMBL3755100 | 0.82 | BRAF (0.67) | BRAF | |
| SCHEMBL22919871 | 0.82 | BRAF (0.64) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-116283916-A | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8546387-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | BRAF 1/4885FLT3 23/4885HCK 408/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | BRAF 1/4885FLT3 23/4885HCK 408/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | BRAF 1/4885FLT3 23/4885HCK 408/4885 |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | BRAF 1/4885FLT3 23/4885HCK 408/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | BRAF 1/4885FLT3 23/4885HCK 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.